Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

NCT05600387 is registered in ClinicalTrials.gov with Zhijun Sun as lead sponsor.

NCT NCT05600387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05600387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Lead sponsor
Zhijun Sun
Phase
Phase 4
Overall status
Unknown status
Start date
November 5, 2022
Completion date
October 31, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, heart failure with mid range ejection fraction, heart failure with preserved ejection fraction